Jean-François Dufour
Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice
Redaelli C, Semela D, Carrick F, Ledermann M, Candinas D, Sauter B, Dufour J. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 2004; 40:305-12.
Feb 1, 2004Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice
Feb 1, 2004J Hepatol 2004; 40:305-12
Redaelli Claudio A, Semela David, Carrick Francine E, Ledermann Monika, Candinas Daniel, Sauter Bernhard, Dufour Jean-François
Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases
Vashist Y, Semela D, Dufour J. Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. Med Hypotheses 2004; 62:82-5.
Jan 1, 2004Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases
Jan 1, 2004Med Hypotheses 2004; 62:82-5
Vashist Yogesh, Semela David, Dufour Jean-François
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C
August-Jörg B, Renner E, Weitz M, Meyenberger C, Hermann R, Henz S, Gonvers J, Dufour J, Borovicka J, Swiss Association for the Study of the Liver. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:455-60.
Aug 23, 2003Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C
Aug 23, 2003Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:455-60
August-Jörg Barbara S E, Renner Eberhard L, Weitz Manfred, Meyenberger Christa, Hermann Rudolf, Henz Samuel, Gonvers Jean-Jacques, Dufour Jean-François, Borovicka Jan, Swiss Association for the Study of the Liver
Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial
Helbling B, Renner E, Sagmeister M, Borovicka J, Steuerwald M, Cathomas G, Reichen J, Dufour J, Gonvers J, Viani F, Stamenic I, Investigators of the Swiss Association for the Study of the Liver. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology (Baltimore, Md.) 2002; 35:447-54.
Feb 1, 2002Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial
Feb 1, 2002Hepatology (Baltimore, Md.) 2002; 35:447-54
Helbling Beat, Renner Eberhard L, Sagmeister Markus, Borovicka Jan, Steuerwald Michael, Cathomas Gieri, Reichen Jurg, Dufour Jean-François, Gonvers Jean-Jacques, Viani Francesco, Stamenic Ivan, Investigators of the Swiss Association for the Study of the Liver